Digital Water Saves Millions for Communities, According to Leading Utilities
8.6.2023 13:00:00 EEST | Business Wire | Press release
Leading water utilities are increasingly embracing data analytics and digital technology to optimize their operations, save millions for communities and increase water networks’ resilience to climate change.
Insights from 18 global water utility leaders and experts that are influential in early-stage digital adoption are featured in a new paper from water technology leader Xylem (NYSE: XYL) and Bluefield Research. These utility experts share perspectives on how “going digital” is helping them to solve big water challenges in their communities. Their shared expertise provides a blueprint to accelerate the modernization of 400,000 water, wastewater, and stormwater systems worldwide.
Utilities that participated in the paper implemented digital technology to save billions of gallons of water, prevent millions of gallons of sewer overflow pollution, and save millions of dollars in energy costs.
For example, in Cincinnati, Ohio, the Metropolitan Sewer District of Greater Cincinnati used data and digital solutions to give its existing infrastructure new capabilities.
“We grabbed our combined sewer overflow monitoring data, flow monitors, and real-time control facilities, and tied them together in a SCADA system. The insights were mind-blowing,” Reese Johnson, Compliance Services Division Superintendent at MSD, said.
In Queensland, Australia, Unitywater used leak detection technology to reduce lost water and revenue, and used smart meters to help reduce leaks for customers.
“We learned a lot from our initial 1000-meter pilot project before launching the smart meter network as a second step. Smart water meters have been a sustainable decision, both environmentally and financially,” Daniel Lambert, Unitywater Executive Manager of Sustainable Infrastructure Solutions, said.
Chinese utility Beijing Drainage Group (BDG) is leveraging digital technologies to optimize energy usage and cut carbon emissions. By implementing a suite of control systems for aeration, chemical dosing, and drainage, BDG has already cut annual energy use by 10 to 15%.
The utility leaders and experts featured in the new paper, Ripple Effect: A Movement Towards Digital Transformation, demonstrate how incremental approaches to digital adoption can lead to powerful outcomes.
“Utilities are transforming the water sector and delivering big benefits for local communities -- saving money, preventing leaks and overflows, and cutting emissions,” Matthew Pine, Chief Operating Officer at Xylem, said. “Learning from the experiences of these pacesetters, utilities of all sizes, and at any stage of digital maturity, can accelerate their transition to more affordable and more sustainable infrastructure.”
View the paper and associated resources at: www.xylem.com/RippleEffect
ENDS
About Xylem
Xylem (XYL) is a leading global water technology company committed to solving the world’s critical water, wastewater, and water-related challenges through technology, innovation, and expertise. Our more than 22,000 diverse employees delivered combined pro forma revenue of $7.3 billion in 2022. We are creating a more sustainable world by enabling our customers to optimize water and resource management and helping communities in more than 150 countries become water-secure. Join us in the effort at www.xylem.com and Let’s Solve Water.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230608005390/en/
Contact information
Houston Spencer
+1 (914) 240-3046
Houston.Spencer@xylem.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Wyss Geneva Steps Into Its Next Chapter11.6.2026 14:33:00 EEST | Press release
The Wyss Center for Bio and Neuroengineering in Geneva is pleased to announce the appointment of Dr. Tracy Laabs as Director, effective July 1st 2026. Dr. Laabs succeeds Prof. Dr. Erwin Böttinger, who leaves behind a fundamentally transformed organization: one that no longer just pursues breakthrough science but systematically turns it into ventures that reach patients. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260611328520/en/ Dr. Tracy Laabs, incoming Director, Wyss Center Geneva Since joining the Wyss Center as Director in April 2023, Prof. Böttinger brought a bold vision: to evolve the Center from a portfolio of promising projects into a disciplined engine for venture creation. Under his leadership, the Center spun off six companies in two years (including ABILITY Neurotech SA and Clee Medical SA in 2025) while simultaneously building a robust pipeline of next-generation programs in AI-guided neuromodulation and min
BeOne Showcases Landmark Phase 3 Data in CLL Patients Aged 80+ at EHA 2026, Reinforcing BRUKINSA Benefit11.6.2026 14:24:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced the presentation of a large Phase 3 dataset in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) aged 80 and older, showing sustained benefit with BRUKINSA after nearly 6.5 years of follow-up, reinforcing its role as the foundational BTK inhibitor. BRUKINSA is the only BTK inhibitor to demonstrate superior efficacy vs. ibrutinib in a Phase 3 trial.1 These data, one of the largest datasets of older patients with treatment-naive CLL, will be presented at the 2026 European Hematology Association (EHA) Congress in Stockholm, Sweden. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: "While the median age of diagnosis for CLL is 70 and the average age of treatment initiation is 75, many pivotal trials still underrepresent the patients that physicians most often see in practice. These data show that the durable benefit of
Clearlake Expands Liquid Credit Platform With Acquisition of LCM Asset Management’s CLO Contracts11.6.2026 14:00:00 EEST | Press release
Clearlake Capital Group, L.P. (“Clearlake” or the “Firm”), a global investment firm managing integrated platforms spanning private equity, liquid and private credit, and other related strategies, today announced that its credit platform, Clearlake Credit, will assume management of CLOs managed by LCM Asset Management, LLC. The transaction adds 31 CLOs representing more than $5 billion of assets under management and increases assets managed by Clearlake Credit to approximately $39 billion across liquid credit, private credit, and other customized credit solutions. The acquisition further broadens the Firm’s capabilities, deepens its relationships with institutional investors, and reinforces its client-centric approach and commitment to seeking attractive risk-adjusted returns across market cycles. Milbank LLP and Dechert LLP represented Clearlake Credit in the transaction. GreensLedge Capital Markets advised the seller. About Clearlake Clearlake Capital is a leading global alternative a
Takeda’s Zasocitinib Significantly Outperforms Deucravacitinib in Head-to-Head Phase 3 Psoriasis Study, Promising to Redefine Oral Treatment Expectations11.6.2026 14:00:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK) announced positive topline results for the Phase 3, randomized, multicenter, double-blind study comparing zasocitinib (TAK-279), an investigational, next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, to deucravacitinib in adults with moderate-to-severe plaque psoriasis (PsO). In the LATITUDE Atlas (TAK-279-PsO-3004) head-to-head study, zasocitinib demonstrated statistical superiority over deucravacitinib for the primary endpoint, Psoriasis Area and Severity Index (PASI) 100 response rate at week 16. The study also demonstrated statistical superiority over deucravacitinib for all key secondary endpoints, including PASI 90 response and Static Physician's Global Assessment (sPGA) 0 at week 16. Zasocitinib was generally well tolerated with a consistent safety and tolerability profile and no new safety signals identified. Perspectives on head-to-head zasocitinib study “In this head-to-head study, zasocitinib clearly demonstrated
L&T Technology Services, Databricks Partner to Deliver Industrial AI at Scale for Asset-Intensive Industries11.6.2026 13:30:00 EEST | Press release
L&T Technology Services (BSE: 540115, NSE: LTTS), a global leader in AI, Digital & ER&D Consulting Services, today announced a strategic go-to-market partnership with Databricks, the leading Data and AI company, to co-develop and deliver Industrial AI solutions that advance Engineering Intelligence (EI) for asset-intensive enterprises. Anchored in LTTS' Sustainability segment, spanning Process Engineering, Discrete Manufacturing and Industrial Products, the partnership will support Energy, Petrochemicals and Industrials clients globally. As industrial organizations seek to unlock greater value from decades of operational and engineering data, the alliance will combine LTTS’ deep domain capabilities with the Databricks platform to transform complex plant data into Engineering Intelligence - enabling improved asset reliability, operational efficiency and sustainability performance. The partnership brings together LTTS’ expertise in forward looking technologies and extensive experience ac
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
